Kandalaft lab

We work on the clinical development of personalized cancer vaccines. The aim is to improve whole tumor lysate vaccination approaches and other personalized cancer vaccine approaches by improving the dendritic cell platform and by choosing the most immunogenic antigen with the most practical preparation to be translated rapidly to the clinic. The other focus of our lab is to find the best setting to integrate vaccines in the standard of care treatment plan for ovarian cancer patients and to understand the immune fitness of cancer patients and correlate it with vaccination. ...


Lana Kandalaft

PhD Associate Professor, Cancer vaccine development, Department of Oncology, Director of Center of experimental therapeutics UNIL & CHUV, Ludwig adjunct scientist, Ludwig Institute for Cancer Research Lausanne


Selected Publications

The current clinical landscape of personalized cancer vaccines.

Fritah H, Rovelli R, Chiang CL, Kandalaft LE

Cancer treatment reviews – 2022 May 1

Vaccines as Priming Tools for T Cell Therapy for Epithelial Cancers.

Kandalaft LE, Harari A

Cancers – 2021 Nov 19

Integrating Cancer Vaccines in the Standard-of-Care of Ovarian Cancer: Translating Preclinical Models to Human.

Chiang CL, Rovelli R, Sarivalasis A, Kandalaft LE

Cancers – 2021 Sep 10

Personalized cancer vaccine strategy elicits polyfunctional T cells and demonstrates clinical benefits in ovarian cancer.

Tanyi JL, Chiang CL, Chiffelle J, (...), Coukos G, Harari A, Kandalaft LE

NPJ vaccines – 2021 Mar 15

Efficacy of cancer vaccines in selected gynaecological breast and ovarian cancers: A 20-year systematic review and meta-analysis.

Dafni U, Martín-Lluesma S, Balint K, (...), Zaman K, Sarivalasis A, Kandalaft LE

European journal of cancer (Oxford, England : 1990) – 2020 Nov 19

Development of an optimized closed and semi-automatic protocol for Good Manufacturing Practice manufacturing of tumor-infiltrating lymphocytes in a hospital environment.

Gannon PO, Harari A, Auger A, (...), Demartines N, Coukos G, Kandalaft LE

Cytotherapy – 2020 Oct 14

Editorial overview: Pharmaceutical biotechnology: new frontiers in cancer immunotherapy.

Kandalaft LE, Graciotti M

Current opinion in biotechnology – 2020 Sep 8

Antitumour dendritic cell vaccination in a priming and boosting approach.

Harari A, Graciotti M, Bassani-Sternberg M, Kandalaft LE

Nature reviews. Drug discovery – 2020 Aug 6

Challenges and advantages of cell therapy manufacturing under Good Manufacturing Practices within the hospital setting.

Iancu EM, Kandalaft LE

Current opinion in biotechnology – 2020 Jul 11

Quantitative and qualitative impairments in dendritic cell subsets of patients with ovarian or prostate cancer.

Mastelic-Gavillet B, Sarivalasis A, Lozano LE, (...), Romero P, Viganó S, Kandalaft LE

European journal of cancer (Oxford, England : 1990) – 2020 Jun 23

Are dendritic cells the most appropriate therapeutic vaccine for patients with ovarian cancer?

Martin-Lluesma S, Graciotti M, Grimm AJ, (...), Boudousquié C, Chiang CL, Kandalaft LE

Current opinion in biotechnology – 2020 Apr 22

A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside.

Chiang CL, Kandalaft LE, Tanyi J, (...), Powell DJ Jr, Mick R, Coukos G

Clinical cancer research : an official journal of the American Association for Cancer Research – 2013 Jul 9

A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer.

Kandalaft LE, Chiang CL, Tanyi J, (...), Balint K, Mick R, Coukos G

Journal of translational medicine – 2013 Jun 18

Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer.

Kandalaft LE, Powell DJ Jr, Chiang CL, (...), Torigian DA, June CH, Coukos G

Oncoimmunology – 2013 Jan 1

Related news


AGORA PRS | June 4th


AGORA Sustainability Day


Invitation Public PhD Thesis Defense – Hajer Fritah, Kandalaft lab


Invitation Public PhD Thesis Defense – Ritaparna Ahmed, Kandalaft lab